IM Cannabis Corp.
IMCC Healthcare Drug Manufacturers Specialty & Generic
IM Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue fell 40.3%, EPS fell 385.7%, free cash flow fell 266.8% and total debt fell 64.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow IMCC
IM Cannabis Corp. (IMCC) Piotroski F-score
IM Cannabis Corp.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, up from 2 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 2.00 |
| FY2024 | 2 | (1.00) |
| FY2023 | 3 | 1.00 |
| FY2022 | 2 | 1.00 |
| FY2021 | 1 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (31.57%) | (23.86%) | Fail | 0 |
| Positive operating cash flow | 3.38m | (786.00k) | Pass | 1 |
| Rising return on assets | (31.57%) | (23.86%) | Fail | 0 |
| Cash flow above net income | 11.48m | 6.94m | Pass | 1 |
| Falling long-term leverage | 0.03 | 0.01 | Fail | 0 |
| Rising current ratio | 0.67 | 0.67 | Fail | 0 |
| No new shares issued | 141,200 | 78,200 | Fail | 0 |
| Rising gross margin | 17.70% | 15.64% | Pass | 1 |
| Rising asset turnover | 1.53 | 1.22 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| YCBD cbdMD, Inc. compare | 6 |
| IMCC IM Cannabis Corp. | 4 |
| GELS Gelteq Limited compare | 4 |
| PTPI Petros Pharmaceuticals, Inc. compare | 4 |
| RDHL Redhill Biopharma Ltd. compare | 3 |
| NEPTF Neptune Wellness Solutions Inc. compare | 3 |
| BTAIQ BioXcel Therapeutics, Inc. compare | 2 |
| AKAN Akanda Corp. compare | 1 |
| PRFX PainReform Ltd. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover